124 related articles for article (PubMed ID: 15103154)
1. Preliminary X-ray analysis of a human V(H) fragment at 1.8 A resolution.
Gaur RK; Kupper MB; Fischer R; Hoffmann KM
Acta Crystallogr D Biol Crystallogr; 2004 May; 60(Pt 5):965-7. PubMed ID: 15103154
[TBL] [Abstract][Full Text] [Related]
2. Structure of a non-camelized human M12-V(H) domain at 1.5A resolution.
Gaur RK
J Struct Biol; 2005 Oct; 152(1):84-9. PubMed ID: 16183303
[TBL] [Abstract][Full Text] [Related]
3. Crystallization and preliminary X-ray diffraction study of an idiotope-anti-idiotope Fv-Fv complex.
Goldbaum FA; Fields BA; Cauerhff A; Ysern X; Houdusse A; Eisele JL; Poljak RJ; Mariuzza RA
J Mol Biol; 1994 Sep; 241(5):739-43. PubMed ID: 8071997
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen.
Kaufmann M; Lindner P; Honegger A; Blank K; Tschopp M; Capitani G; Plückthun A; Grütter MG
J Mol Biol; 2002 Apr; 318(1):135-47. PubMed ID: 12054774
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.
Jespers L; Schon O; James LC; Veprintsev D; Winter G
J Mol Biol; 2004 Apr; 337(4):893-903. PubMed ID: 15033359
[TBL] [Abstract][Full Text] [Related]
6. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
Jung S; Spinelli S; Schimmele B; Honegger A; Pugliese L; Cambillau C; Plückthun A
J Mol Biol; 2001 Jun; 309(3):701-16. PubMed ID: 11397090
[TBL] [Abstract][Full Text] [Related]
7. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65.
Eigenbrot C; Gonzalez T; Mayeda J; Carter P; Werther W; Hotaling T; Fox J; Kessler J
Proteins; 1994 Jan; 18(1):49-62. PubMed ID: 7908437
[TBL] [Abstract][Full Text] [Related]
8. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
Honegger A; Malebranche AD; Röthlisberger D; Plückthun A
Protein Eng Des Sel; 2009 Mar; 22(3):121-34. PubMed ID: 19136675
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of a human VH: requirements for maintaining a monomeric fragment.
Dottorini T; Vaughan CK; Walsh MA; LoSurdo P; Sollazzo M
Biochemistry; 2004 Jan; 43(3):622-8. PubMed ID: 14730966
[TBL] [Abstract][Full Text] [Related]
10. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
Narayanan A; Sellers BD; Jacobson MP
J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
[TBL] [Abstract][Full Text] [Related]
11. Structural consequences of humanizing an antibody.
Holmes MA; Foote J
J Immunol; 1997 Mar; 158(5):2192-201. PubMed ID: 9036965
[TBL] [Abstract][Full Text] [Related]
12. The pH-dependent structural variation of complementarity-determining region H3 in the crystal structures of the Fv fragment from an anti-dansyl monoclonal antibody.
Nakasako M; Takahashi H; Shimba N; Shimada I; Arata Y
J Mol Biol; 1999 Aug; 291(1):117-34. PubMed ID: 10438610
[TBL] [Abstract][Full Text] [Related]
13. Design and validation of a synthetic VH repertoire with tailored diversity for protein recognition.
Almagro JC; Quintero-Hernández V; Ortiz-León M; Velandia A; Smith SL; Becerril B
J Mol Recognit; 2006; 19(5):413-22. PubMed ID: 16881059
[TBL] [Abstract][Full Text] [Related]
14. A human antibody fragment with high affinity for biodegradable polymer film.
Watanabe H; Tsumoto K; Taguchi S; Yamashita K; Doi Y; Nishimiya Y; Kondo H; Umetsu M; Kumagai I
Bioconjug Chem; 2007; 18(3):645-51. PubMed ID: 17385839
[TBL] [Abstract][Full Text] [Related]
15. Enhanced conformational diversity search of CDR-H3 in antibodies: role of the first CDR-H3 residue.
Kim ST; Shirai H; Nakajima N; Higo J; Nakamura H
Proteins; 1999 Dec; 37(4):683-96. PubMed ID: 10651282
[TBL] [Abstract][Full Text] [Related]
16. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic analysis of the NNA7 Fab and proposal for the mode of human blood-group recognition.
Xie K; Song SC; Spitalnik SL; Wedekind JE
Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1386-94. PubMed ID: 16204891
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of a shark single-domain antibody V region in complex with lysozyme.
Stanfield RL; Dooley H; Flajnik MF; Wilson IA
Science; 2004 Sep; 305(5691):1770-3. PubMed ID: 15319492
[TBL] [Abstract][Full Text] [Related]
19. Direct evidence by H/D exchange and ESI-MS for transient unproductive domain interaction in the refolding of an antibody scFv fragment.
Jäger M; Plückthun A
Protein Sci; 2000 Mar; 9(3):552-63. PubMed ID: 10752617
[TBL] [Abstract][Full Text] [Related]
20. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
Tanha J; Nguyen TD; Ng A; Ryan S; Ni F; Mackenzie R
Protein Eng Des Sel; 2006 Nov; 19(11):503-9. PubMed ID: 16971398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
